Skip to content

US · EVMN · BIOTECHNOLOGY

Evommune, Inc. (EVMN) intrinsic value and stock valuation

$7.04as of 2026-11-21 · Mkt cap 184.42M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Evommune, Inc. DCF and intrinsic value

InvestorsCraft values EVMN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from EVMN’s statements →

Evommune, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Palo Alto, CA 94304 evommune.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$13M
20232025
Net income
-$-68.87M
20232025
Free cash flow
-$-76.68M
20232025
Total equity
$205.6M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$13M$7M$5M
Operating income-$-81.07M-$-70.01M-$-37.85M
Net income-$-68.87M-$-66.81M-$-34.05M
EPSd-$-2.18M-$-2.22M-$-1.13M
Operating cash flow-$-76.44M-$-58.2M-$-29.97M
Capital expenditure-$-230K-$-90K-$-120K
Free cash flow-$-76.68M-$-58.28M-$-30.09M
Total assets$225M$76.1M$82.3M
Total debt$2.06M$193.3M$150.6M
Net debt-$-42M$177.1M$121.6M
Total equity$205.6M-$-144.24M-$-77.71M
Cash and short-term investments$149.2M$72M$79.1M
Income statement
202520242023
Revenue$13M$7M$5M
Cost of revenue$0.00$1.29M$1M
Gross profit$13M$5.71M$4M
Research and development expenses$74M$64.2M$32M
Selling, general and administrative expenses$20M$11.5M$9.85M
Other expenses$0.00$0.00$0.00
Operating expenses$94.1M$75.7M$41.9M
Cost and expenses$94.1M$77M$42.9M
Interest income$3.32M$3.24M$3.86M
Interest expense$0.00$30K$60K
Depreciation and amortization$1.39M$1.29M$1M
Ebitda-$-67.48M-$-65.49M-$-32.99M
Operating income-$-81.07M-$-70.01M-$-37.85M
Total other income/expenses, net$12.2M$3.2M$3.8M
Income before tax-$-68.87M-$-66.81M-$-34.05M
Income tax expense$0.00$0.00$0.00
Net income-$-68.87M-$-66.81M-$-34.05M
Weighted average shares outstanding$31.5M$30.1M$30.1M
Weighted average diluted shares outstanding$31.5M$30.1M$30.1M
Balance sheet
202520242023
Cash and short-term investments$149.2M$72M$79.1M
Net receivables$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Total current assets$153.5M$74M$80M
Property, plant and equipment, net$2.46M$1.8M$1.97M
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$68.9M$210K$210K
Total non-current assets$71.5M$2.07M$2.22M
Total assets$225M$76.1M$82.3M
Accounts payable$7.76M$8.26M$1.76M
Short-term debt$590K$1.02M$770K
Deferred revenue$0.00$3M$0.00
Total current liabilities$17.9M$28M$6.86M
Long-term debt$1.47M$192.3M$149.9M
Deferred revenue, non-current$0.00$0.00$3M
Total non-current liabilities$1.47M$192.3M$153.1M
Capital lease obligations$1.47M$520K$490K
Total liabilities$19.4M$220.3M$160M
Common stock$0.00$0.00$0.00
Retained earnings-$-221.09M-$-152.22M-$-83.91M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$205.6M-$-144.24M-$-77.71M
Total investments$174M$56M$50.3M
Total debt$2.06M$193.3M$150.6M
Net debt-$-42M$177.1M$121.6M
Cash flow statement
202520242023
Net income-$-68.87M-$-66.81M-$-34.05M
Depreciation and amortization$1.39M$1.29M$1M
Stock-based compensation$0.00$0.00$0.00
Change in working capital-$-4.12M$7.42M$3.34M
Accounts receivable$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Accounts payable-$-840K$6.51M$120K
Net cash provided by operating activities-$-76.44M-$-58.2M-$-29.97M
Investments in property, plant and equipment-$-230K-$-90K-$-120K
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities-$-115.31M-$-3.99M-$-48.43M
Common stock issued$222.4M$49.8M$64M
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$220.8M$49.4M$63.8M
Net change in cash$27.8M-$-12.77M$29M
Cash at end of period$44.1M$16.3M$29M
Operating cash flow-$-76.44M-$-58.2M-$-29.97M
Capital expenditure-$-230K-$-90K-$-120K
Free cash flow-$-76.68M-$-58.28M-$-30.09M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Evommune, Inc.

        Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

        CEO
        Luis C. Pena
        Employees
        48
        Beta
        0.96

        Explore

        Frequently asked questions

        What is the intrinsic value of Evommune, Inc. (EVMN)?

        Evommune, Inc. (EVMN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is EVMN undervalued?

        EVMN trades at a price of $7.04 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.